Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HY-007
- Development stage
- Discontinued
- Lead developer
- Juventas Cell Therapy
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
HY-007 is a chimeric antigen receptor (CAR) T-cell therapy product that targets both CD123 (interleukin-3 receptor alpha-subunit) and CD33 antigens. It was developed for the treatment of hematological malignancies, particularly acute myeloid leukemia (AML). The dual targeting of CD123 and CD33 aims to enhance anti-leukemic efficacy by addressing tumor heterogeneity and reducing the risk of relapse due to antigen escape. The drug was initially developed by Juventas Cell Therapy.
- Other names
- HY 007HY007HY-007
02
Targets
IL3RA (Interleukin 3 Receptor)CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on HY-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HY-007.